Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib.

Noda S, Kageyama S, Tsuru T, Kubota S, Yoshida T, Okamoto K, Okada Y, Morita SY, Terada T.

Case Rep Oncol. 2012 Sep;5(3):627-32. doi: 10.1159/000345694. Epub 2012 Sep 21.

2.

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.

Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D.

Cancer Chemother Pharmacol. 2008 Mar;61(3):515-24. Epub 2007 May 16.

PMID:
17505827
3.
4.

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ.

Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71. doi: 10.1007/s00280-009-1170-y. Epub 2009 Dec 5. Review.

PMID:
19967539
5.

Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.

Yildiz I, Sen F, Kilic L, Ciftci R, Basaran M.

Korean J Urol. 2014 Jan;55(1):74-6. doi: 10.4111/kju.2014.55.1.74. Epub 2014 Jan 15.

6.

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.

Houk BE, Bello CL, Kang D, Amantea M.

Clin Cancer Res. 2009 Apr 1;15(7):2497-506. doi: 10.1158/1078-0432.CCR-08-1893. Epub 2009 Mar 3.

7.

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.

Narjoz C, Cessot A, Thomas-Schoemann A, Golmard JL, Huillard O, Boudou-Rouquette P, Behouche A, Taieb F, Durand JP, Dauphin A, Coriat R, Vidal M, Tod M, Alexandre J, Loriot MA, Goldwasser F, Blanchet B.

Invest New Drugs. 2015 Feb;33(1):257-68. doi: 10.1007/s10637-014-0178-2. Epub 2014 Oct 25.

PMID:
25344452
8.

Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.

Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF.

BJU Int. 2012 Sep;110(5):692-8. doi: 10.1111/j.1464-410X.2012.10946.x. Epub 2012 Feb 24.

9.

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY.

Cancer. 2012 Mar 1;118(5):1252-9. doi: 10.1002/cncr.26440. Epub 2011 Sep 6.

10.

Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.

Li XS, Wu X, Zhao PJ, Huang LH, Song Y, Gong K, Shen C, Yu W, Song G, Zhao Z, Zhang Z, Zhang Q, Wang G, He ZS, Zhou LQ, Jin J.

Chin Med J (Engl). 2011 Sep;124(18):2920-4.

11.

Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.

Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K, Okada Y, Kawauchi A, Onishi H, Hira D, Morita SY, Terada T.

Clin Genitourin Cancer. 2015 Aug;13(4):350-8. doi: 10.1016/j.clgc.2015.01.007. Epub 2015 Jan 21.

PMID:
25701374
12.

Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations.

Hashita T, Katsuyama Y, Nakamura K, Momose Y, Komatsu D, Koide N, Miyagawa S, Nakamura T, Yamamoto K, Ohmori S.

Oncol Lett. 2012 Sep;4(3):501-504. Epub 2012 Jun 28.

13.

Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.

Ansari J, Fatima A, Fernando K, Collins S, James ND, Porfiri E.

Oncol Rep. 2010 Aug;24(2):507-10.

PMID:
20596640
14.

Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.

Yoon SH, Kim KH, Choi J, Kim GM, Kim JH, Kim HS, Park YN, Rha SY.

Cancer Res Treat. 2010 Sep;42(3):180-4. doi: 10.4143/crt.2010.42.3.180. Epub 2010 Sep 30.

15.

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.

Etienne-Grimaldi MC, Renée N, Izzedine H, Milano G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3757-61. doi: 10.1016/j.jchromb.2009.09.011. Epub 2009 Sep 17.

PMID:
19797000
16.

Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.

Shinsako K, Mizuno T, Terada T, Watanabe J, Kamba T, Nakamura E, Ogawa O, Inui K.

Int J Clin Oncol. 2010 Oct;15(5):512-4. doi: 10.1007/s10147-010-0070-9. Epub 2010 Mar 26.

PMID:
20340037
17.

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.

Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF, Powles T, Chowdhury P, Karapetis C, Harper PG, Choueiri TK, Chowdhury S.

BJU Int. 2011 Oct;108(8):1279-83. doi: 10.1111/j.1464-410X.2010.09990.x. Epub 2011 Jan 18.

18.

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.

Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U.

Oncology. 2009;76(5):350-4. doi: 10.1159/000209961. Epub 2009 Mar 24.

PMID:
19321976
19.

Phase II study of sunitinib malate in head and neck squamous cell carcinoma.

Choong NW, Kozloff M, Taber D, Hu HS, Wade J 3rd, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EE.

Invest New Drugs. 2010 Oct;28(5):677-83. doi: 10.1007/s10637-009-9296-7. Epub 2009 Aug 4.

PMID:
19649772
20.

[Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].

van der Veldt AA, van den Eertwegh AJ, Boven E.

Ned Tijdschr Geneeskd. 2007 May 19;151(20):1142-7. Dutch.

PMID:
17557672
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk